Literature DB >> 25051460

Inpatient rehabilitation performance of patients with paraneoplastic cerebellar degeneration.

Jack B Fu1, Vishwa S Raj2, Arash Asher3, Jay Lee4, Ying Guo5, Benedict S Konzen5, Eduardo Bruera5.   

Abstract

OBJECTIVE: To evaluate the functional improvement of rehabilitation inpatients with paraneoplastic cerebellar degeneration.
DESIGN: Retrospective review.
SETTING: Referral-based hospitals. PARTICIPANTS: Cancer rehabilitation inpatients (N=7) admitted to 3 different cancer centers with a diagnosis of paraneoplastic cerebellar degeneration. INTERVENTION: Medical records were retrospectively analyzed for demographic, laboratory, medical, and functional data. MAIN OUTCOME MEASURE: FIM.
RESULTS: All 7 patients were white women (median age, 62y). Primary cancers included ovarian carcinoma (n=2), small cell lung cancer (n=2), uterine carcinoma (n=2), and invasive ductal breast carcinoma (n=1). Mean admission total FIM score was 61±23.97. Mean discharge total FIM score was 73.6±29.35. The mean change in total FIM score was 12.6 (P=.0018). The mean length of rehabilitation stay was 17.1 days. The mean total FIM efficiency was .73. Of the 7 patients, 5 (71%) were discharged home, 1 (14%) was discharged to a nursing home, and 1 (14%) was transferred to the primary acute care service.
CONCLUSIONS: To our knowledge, this is the first study to demonstrate the functional performance of a group of rehabilitation inpatients with paraneoplastic cerebellar degeneration. Despite the poor neurologic prognosis associated with this syndrome, these patients made significant functional improvements in inpatient rehabilitation. When appropriate, inpatient rehabilitation should be considered. Further studies with larger sample sizes are needed.
Copyright © 2014 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inpatients; Paraneoplastic cerebellar degeneration; Rehabilitation

Mesh:

Year:  2014        PMID: 25051460      PMCID: PMC4252784          DOI: 10.1016/j.apmr.2014.07.003

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  8 in total

1.  Cancer rehabilitation.

Authors:  Andrea L Cheville
Journal:  Semin Oncol       Date:  2005-04       Impact factor: 4.929

Review 2.  Paraneoplastic syndromes affecting the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  Semin Oncol       Date:  2006-06       Impact factor: 4.929

3.  Paraneoplastic cerebellar degeneration as the first evidence of cancer: a case report.

Authors:  S Liu; R Tunkel; E Lachmann; W Nagler
Journal:  Arch Phys Med Rehabil       Date:  2000-06       Impact factor: 3.966

4.  Paraneoplastic subacute cerebellar degeneration: functional improvement and the role of rehabilitation.

Authors:  J A Sliwa; S Thatcher; J Jet
Journal:  Arch Phys Med Rehabil       Date:  1994-03       Impact factor: 3.966

5.  Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.

Authors:  Setareh Shams'ili; Joost Grefkens; Bertie de Leeuw; Martin van den Bent; Herbert Hooijkaas; Bronno van der Holt; Charles Vecht; Peter Sillevis Smitt
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

6.  Rehabilitation treatment options for a patient with paraneoplastic cerebellar degeneration.

Authors:  Erica Perlmutter; Patricia C Gregory
Journal:  Am J Phys Med Rehabil       Date:  2003-02       Impact factor: 2.159

7.  Comparison of functional outcomes in low- and high-grade astrocytoma rehabilitation inpatients.

Authors:  Jack B Fu; Henrique A Parsons; Ki Y Shin; Ying Guo; Benedict S Konzen; Rajesh R Yadav; Dennis W Smith
Journal:  Am J Phys Med Rehabil       Date:  2010-03       Impact factor: 2.159

8.  Treatment of paraneoplastic cerebellar degeneration.

Authors:  John E Greenlee
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

  8 in total
  9 in total

Review 1.  A Guide to Inpatient Cancer Rehabilitation: Focusing on Patient Selection and Evidence-Based Outcomes.

Authors:  Jack B Fu; Vishwa S Raj; Ying Guo
Journal:  PM R       Date:  2017-09       Impact factor: 2.298

2.  [Paraneoplastic cerebellar degeneration (PCD) - an interdisciplinary challenge in neurology, oncology and palliative care].

Authors:  Sabine Burger; Stefan Lorenzl
Journal:  Wien Med Wochenschr       Date:  2018-02-06

Review 3.  Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review.

Authors:  M Le May; S Dent
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

4.  Characteristics of Cancer Rehabilitation Fellowship Training Programs in the USA.

Authors:  Rajesh R Yadav; An T Ngo-Huang; Amy Ng; Jack B Fu; Christian Custodio; Eric Wisotzky; Raj Mitra; Eduardo Bruera
Journal:  J Cancer Educ       Date:  2018-12       Impact factor: 2.037

Review 5.  Update on neurological paraneoplastic syndromes.

Authors:  Romana Höftberger; Myrna R Rosenfeld; Josep Dalmau
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

Review 6.  The Intersection of Oncology Prognosis and Cancer Rehabilitation.

Authors:  Sean Robinson Smith; Jasmine Yiqian Zheng
Journal:  Curr Phys Med Rehabil Rep       Date:  2017-03-01

Review 7.  Rehabilitation for a patient with anti-Yo antibody-positive paraneoplastic cerebellar degeneration caused by breast cancer: A case report and literature review.

Authors:  Naoki Kato; Goichi Hashida; Kuni Konaka
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

8.  Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature.

Authors:  Mathew Chatham; Polly Niravath
Journal:  Cureus       Date:  2021-12-06

9.  Unilateral Arm Urticaria Presenting as a Paraneoplastic Manifestation of Metachronous Bilateral Breast Cancer.

Authors:  Pashtoon Murtaza Kasi; Tina J Hieken; Tufia C Haddad
Journal:  Case Rep Oncol       Date:  2016-01-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.